Oncology
Practical Solutions to Optimize mCRC Biomarker Testing
The emerging interest and requests for biomarker testing for colon cancer has led to a shift away from a one-size-fits-all approach and towards a precision-based methodology to optimize patient care and patient outcomes. Biomarkers are becoming standard practice in guiding targeted and conventional therapies for patients with CRC and advancing personalized care for improved clinical […]
DURATION
20 min
PROFESSION
Physician
# OF CREDITS
0
ACCREDITATION
Unaccredited
EXPIRY DATE
2023-06-28
The emerging interest and requests for biomarker testing for colon cancer has led to a shift away from a one-size-fits-all approach and towards a precision-based methodology to optimize patient care and patient outcomes. Biomarkers are becoming standard practice in guiding targeted and conventional therapies for patients with CRC and advancing personalized care for improved clinical outcomes. In this expert brief, Dr. Sharlene Gill and Dr. Brandon Sheffield address the collaborative role of the pathologist and oncologist in facilitating timely biomarker testing and discuss the use of biomarkers to optimize metastatic colorectal cancer care.
This program has received an educational grant or in-kind support from Amgen Canada.
Faculty
Brandon Sheffield, MD, FRCPC
Sharlene Gill, MD, MPH, MBA
Learning objectives
After viewing this expert brief, participants will be better able to:
- Recognize the importance of biomarker testing in the management of metastatic colorectal cancer
- Apply recommendations for biomarker testing to improve efficiency and minimize delays
- Understand current and upcoming guidance and standards for colorectal cancer biomarker testing in metastatic colorectal cancer